Ciclosporin/lansoprazole - Perle Biosciences

Drug Profile

Ciclosporin/lansoprazole - Perle Biosciences

Alternative Names: Lansoprazole/ciclosporin - Perle Biosciences

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Perle Bioscience
  • Class Antihyperglycaemics; Benzimidazoles; Ciclosporins; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (PO)
  • 17 Apr 2016 Perle Bioscience withdraws a phase III trial for Type 1 diabetes mellitus (In Children, In adolescents, In adults) in USA (NCT01762657)
  • 02 Jan 2013 Preclinical trials in Type-1 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top